^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SL-279252

    i
    Other names: SL-279252, TAK-252, PD1-Fc-OX40L
    Associations

    News

    Trials
    Company:
    Shattuck
    Drug class:
    PD1 inhibitor, OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=49, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | N=87 --> 49
    Trial completion • Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    SL-279252
    1year
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Active, not recruiting, Shattuck Labs, Inc. | Trial primary completion date: Jul 2023 --> Dec 2023
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    almost2years
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Active, not recruiting, Shattuck Labs, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    almost2years
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Recruiting, Shattuck Labs, Inc. | Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Nov 2022 --> Jul 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    almost3years
    SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (clinicaltrials.gov)
    P1, N=87, Recruiting, Shattuck Labs, Inc. | Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Feb 2022 --> Sep 2022
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    EGFR mutation • MSI-H/dMMR • ALK fusion
    |
    SL-279252
    3years
    Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas (SITC 2021)
    Trends for PK/PD effects at ≥1 mg/kg suggests dose exploration in PD-L1 expressing cancers is warranted beyond 6 mg/kg. Trial Registration NCT03894618
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    SL-279252